Company news
Tvardi Therapeutics, Inc. news in 2021
Tvardi Therapeutics, Inc.'s news releases, calls and decks from 2021, newest first.
Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection
December 19, 2021
Cara Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 17, 2021
Cara Therapeutics Reports Third Quarter 2021 Financial Results
November 7, 2021
Cara Therapeutics Announces CEO Transition
November 2, 2021
Cara Therapeutics to Announce Third Quarter 2021 Financial Results on November 8, 2021
October 31, 2021
Cara Therapeutics Presents Late-Breaking Results of KARE Phase 2 Trial of Oral Difelikefalin (Oral KORSUVA™) in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress
October 3, 2021
Cara Therapeutics Announces Late-Breaking Presentation at 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress
September 28, 2021
Cara Therapeutics to Present at the the 2021 Cantor Virtual Global Healthcare Conference
September 23, 2021
Vifor Pharma and Cara Therapeutics announce U.S. FDA approval of KORSUVA™ injection for the treatment of moderate-to-severe pruritus in hemodialysis patients
August 23, 2021
Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients
August 22, 2021
Cara Therapeutics Reports Second Quarter 2021 Financial Results
August 8, 2021
Cara Therapeutics to Announce Second Quarter 2021 Financial Results on August 9, 2021
August 1, 2021
SWK Holdings' Subsidiary, Enteris BioPharma, Receives $10 Million Milestone Payment from Cara Therapeutics
June 10, 2021
Cara Therapeutics Reports First Quarter 2021 Financial Results
May 9, 2021